No profile data available.
Immutep Limited (IMMP) is a healthcare company in the additional cancer treatment drugs industry, based in Sydney, Australia.
It reported revenue of 14.56 million AUD for fiscal year 2026, and net income of -79.30 million AUD. Its market capitalization was $26.75 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended June 30, 2026; market data as of October 9, 2026.
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Immutep reported 14.56 million AUD in revenue for fiscal year 2026.
$26.75 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include TransCode Therapeutics, Inc. (RNAZ), Context Therapeutics Inc. (CNTX), Intensity Therapeutics, Inc. (INTS), Shuttle Pharmaceuticals Holdings, Inc. (SHPH).